Tetracycline

證據等級: L5

預測適應症: 4 個

Tetracycline: From Broad-Spectrum Bacterial Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Tetracycline is a broad-spectrum antibiotic with long-established use against bacterial infections, including Chlamydia trachomatis. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, but this direction is currently supported by only 1 case report and no registered clinical trials, and the drug is not marketed in New Zealand.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack — no NZ-approved indication text exists because the drug is not marketed. Tetracycline is generically used as a broad-spectrum antibacterial.
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.58%
Evidence Level	L4
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, tetracycline is a member of the tetracycline antibiotic class, which inhibits bacterial protein synthesis and has long-established activity against Chlamydia trachomatis — the causative organism of trachoma and inclusion (follicular) conjunctivitis, for which oral tetracyclines are a traditional first-line treatment.

Punctate epithelial keratoconjunctivitis can occur as a corneal complication following chlamydial follicular conjunctivitis. The mechanistic rationale here is therefore an extension of a well-known class effect (anti-chlamydial activity) rather than a novel target discovered specifically for tetracycline — the sole supporting reference describes recurrence of punctate keratitis after successful antibiotic treatment of the underlying conjunctivitis, not direct evidence that tetracycline treats the keratitis itself.

Given the absence of any clinical trial data and only a single 1992 case report, this should be treated as a research hypothesis derived from class knowledge rather than a validated repurposing signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1424659	1992	Case Report	Cornea	Two cases of chlamydial follicular conjunctivitis treated with oral tetracycline/doxycycline subsequently developed recurrent, bilateral punctate epithelial keratitis; the keratitis followed resolution of the conjunctivitis rather than responding directly to the antibiotic.

Safety Considerations

Please refer to the package insert for safety information.

(Note: a Blocking-severity data gap exists for TFDA/package-insert warnings and contraindications — this must be resolved before any S1 safety review can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for this specific indication is limited to a single case report (L4) with no clinical trial support, and the drug is currently not marketed in New Zealand (0 authorizations). A Blocking-severity data gap on safety warnings/contraindications also precludes a preliminary safety assessment (S1).

To proceed, the following is needed:

TFDA/package insert warnings and contraindications (Blocking gap — required before S1 safety evaluation)
Confirmed mechanism of action data from DrugBank
Additional clinical or observational evidence directly evaluating tetracycline (not just class-mates like doxycycline) in ocular chlamydial disease
New Zealand market-entry assessment, since the drug currently has zero authorizations
Consider evaluating chronic rhinosinusitis (rank 3 in this evidence pack, L3, 4 completed/terminated trials) as an alternative candidate with a substantially stronger evidence base — though note those trials studied doxycycline, not tetracycline itself, so the same class-effect caveat applies.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.